View More View Less
  • 1 Pécsi Tudományegyetem, Általános Orvostudományi Kar, Klinikai Központ, Pécs, Ifjúság útja 20., 7624
  • 2 Pécsi Tudományegyetem, Általános Orvostudományi Kar, Klinikai Központ, Pécs
  • 3 Pécsi Tudományegyetem, Általános Orvostudományi Kar, Klinikai Központ, Pécs
  • 4 Magyar Honvédség Egészségügyi Központ, Budapest
  • 5 Szegedi Tudományegyetem, Általános Orvostudományi Kar, Szeged
  • 6 Gottsegen György Országos Kardiológiai Intézet, Budapest
  • 7 Semmelweis Egyetem, Általános Orvostudományi Kar, Budapest
  • 8 Pécsi Tudományegyetem, Egészségtudományi Kar, Pécs
  • 9 Budai Irgalmasrendi Kórház, Budapest
  • 10 Debreceni Egyetem, Általános Orvostudományi Kar, Debrecen
Open access

Absztrakt

A szíveredetű natriureticus peptidek (B típusú natriureticus peptid, pre-prohormon B típusú natriureticus peptid) fontos szerepet játszanak a cardiovascularis homeostasisban, többek között vasodilatatiós, natriureticus, diuretikus és antiproliferatív hatásaik által. A natriureticus peptidek szakszerű mérésével dyspnoe esetén eldönthető, hogy respirációs vagy cardialis eredetű, lehetséges a szívelégtelenség korai diagnózisa, a szívbetegség súlyosságának elbírálása (prognózis) és a kezelés hatékonyságának monitorozása. Sok országban mérése nagyon elterjedt akár a szakvizsgálat első lépcsőjeként a szív érintettségének eldöntésére. Eddigi elméleti és klinikai vizsgálatok nemcsak megerősítették, hogy a natriureticus peptideknek helye van a mindennapi betegellátásban, hanem napjainkra nemzetközi ajánlások is rendelkezésre állnak ezen biomarkerek gyakorlati alkalmazásáról. A szerzők a dolgozatban áttekintik a natriureticus peptidek hazai mérésének problémakörét, beleértve a laboratóriumi, kardiológiai és egészség-gazdaságtani vonatkozásokat. Orv. Hetil., 2015, 156(31), 1235–1245.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1

    Ziskoven, D., Forssmann, W. G., Holthausen, U., et al.: Calcium-calmodulinantagonists influence release of Cardiodilatin/ANP from atrial cardiocytes. In: Kaufmann, W., Wambach, G. (eds.): Endocrinology of the heart. Springer-Verlag, Berlin, 1989.

  • 2

    Bhalla, V., Willis, S., Maisel, A. S.: B-type natriuretic peptide: the level and the drug – partners in the diagnosis of congestive heart failure. Congest. Heart Fail., 2004, 10(Suppl. 1), 3–27.

  • 3

    Hystad, M. E., Geiran, O. R., Attramadal, H., et al.: Regional cardiac expression and concentration of natriuretic peptides in patients with severe chronic heart failure. Acta Physiol. Scand., 2001, 171(4), 395–403.

  • 4

    Mukoyama, M., Nakao, K., Saito, Y., et al.: Human brain natriuretic peptide, a novel cardiac hormone. Lancet, 1990, 335(8692), 801–802.

  • 5

    Potter, L. R., Abbey-Hosch, S., Dickey, D. M.: Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr. Rev., 2006, 27(1), 47–72.

  • 6

    Daniels, L. B., Allison, M. A., Clopton, P., et al.: Use of natriuretic peptides in pre-participation screening of college athletes. Int. J. Cardiol., 2008, 124(3), 411–414.

  • 7

    Redfield, M. M., Rodeheffer, R. J., Jacobsen, S. J., et al.: Plasma brain natriuretic peptide concentration: impact of age and gender. J. Am. Coll. Cardiol., 2002, 40(5), 976–982.

  • 8

    Wang, T. J., Larson, M. G., Levy, D., et al.: Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am. J. Cardiol., 2002, 90(3), 254–258.

  • 9

    Baggish, A. L., van Kimmenade, R. R., Januzzi, J. L. Jr.: The differential diagnosis of an elevated amino-terminal pro-B-type natriuretic peptide level. Am. J. Cardiol., 2008, 101(3 Suppl.), S43–S48.

  • 10

    Don-Wauchope, A. C., McKelvie, R. S.: Evidence based application of BNP/NT-proBNP testing in heart failure. Clin. Biochem., 2015, 48(4–5), 236–246.

  • 11

    McMurray, J. J., Adamopoulos, S., Anker, S. D., et al.: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. Heart J., 2012, 33(14), 1787–1847.

  • 12

    Mant, J., Doust, J., Roalfe, A., et al.: Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technol. Assess., 2009, 13(32), 1–232.

  • 13

    Maisel, A. S., Krishnaswamy, P., Nowak, R. M., et al.: Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N. Engl. J. Med., 2002, 347(3), 161–167.

  • 14

    McCullough, P. A., Nowak, R. M., McCord, J., et al.: B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure. Analysis from Breathing Not Properly (BNP) Multinational Study. Circulation, 2002, 106(4), 416–422.

  • 15

    McCullough, P. A., Duc, P., Omland, T., et al.: B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am. J. Kidney Dis., 2003, 41(3), 571–579.

  • 16

    Wang, T. J., Larson, M. G., Levy, D., et al.: Impact of obesity on plasma natriuretic peptide levels. Circulation, 2004, 109(5), 594–600.

  • 17

    Januzzi, J. L. Jr., Camargo, C. A., Anwaruddin, S., et al.: The N-terminal Pro-BNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Am. J. Cardiol., 2005, 95(8), 948–954.

  • 18

    Januzzi, J. L. Jr., Chen-Tournoux, A. A., Moe, G.: Amino-terminal pro-B-type natriuretic peptide testing for the diagnosis or exclusion of heart failure in patients with acute symptoms. Am. J. Cardiol., 2008, 101(3 Suppl.), S29–S38.

  • 19

    Thygesen, K., Mair, J., Mueller, C., et al.: Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. Eur. Heart J., 2012, 33(16), 2001–2006.

  • 20

    Januzzi, J. L., van Kimmenade, R., Lainchbury, J., et al.: NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients. The International Collaborative of NT-proBNP Study. Eur. Heart J., 2006, 27(3), 330–337.

  • 21

    Moe, G. W., Ezekowitz, J. A., O’Meara, E., et al.: The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: Anemia, Biomarkers, and Recent Therapeutic Trial Implications. Can. J. Cardiol., 2015, 31(1), 3–16.

  • 22

    Yancy, C. W., Jessup, M., Bozkurt, B., et al.: 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol., 2013, 62(16), e147–e239.

  • 23

    Van Kimmenade, R. R., Pinto, Y. M., Bayes-Genis, A., et al.: Usefulness of intermediate amino-terminal pro-brain natriuretic peptide concentrations for diagnosis and prognosis of acute heart failure. Am. J. Cardiol., 2006, 98(3), 386–390.

  • 24

    Fonarow, G. C., Peacock, W. F., Horwich, T. B., et al.: Usefulness of B-type natriuretic peptide and cardiac troponin levels to predict in-hospital mortality from ADHERE. Am. J. Cardiol., 2008, 101(2), 231–237.

  • 25

    Maisel, A., Hollander, J. E., Guss, D., et al.: Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT): a multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J. Am. Coll. Cardiol., 2004, 44(6), 1328–1333.

  • 26

    Eurlings, L. W., Sanders-van Wijk, S., van Kimmenade, R., et al.: Multimarker strategy for short-term risk assessment in patients with dyspnea in the emergency department: The MARKED (Multi mARKer Emergency Dyspnea)-risk score. J. Am. Coll. Cardiol., 2012, 60(17), 1668–1677.

  • 27

    Zairis, M. N., Tsiaousis, G. Z., Georgilas, A. T., et al.: Multimarker strategy for the prediction of 31 days cardiac death in patients with acutely decompensated chronic heart failure. Int. J. Cardiol., 2010, 141(3), 284–290.

  • 28

    Januzzi, J. L. Jr., Sakhuja, R., O’Donoghue, M., et al.: Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch. Intern. Med., 2006, 166(3), 315–320.

  • 29

    Maeda, K., Tsutamoto, T., Wada, A., et al.: High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J. Am. Coll. Cardiol., 2000, 36(5), 1587–1593.

  • 30

    Anand, I. S., Fisher, L. D., Chiang, Y. T., et al.: Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation, 2003, 107(9), 1278–1283.

  • 31

    Cleland, J. G., McMurray, J. J., Kjekshus, J., et al.: Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J. Am. Coll. Cardiol., 2009, 54(20), 1850–1859.

  • 32

    Berger, R., Huelsman, M., Strecker, K., et al.: B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation, 2002, 105(20), 2392–2397.

  • 33

    Bettencourt, P., Azevedo, A., Pimenta, J., et al.: N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation, 2004, 110(15), 2168–2174.

  • 34

    Logeart, D., Thabut, G., Jourdain, P., et al.: Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J. Am. Coll. Cardiol., 2004, 43(4), 635–641.

  • 35

    Di Somma, S., Magrini, L., Pittoni, V., et al.: In-hospital percentage BNP reduction is highly predictive for adverse events in patients admitted for acute heart failure: the Italian RED study. Crit. Care, 2010, 14(3), R116.

  • 36

    Salah, K., Kok, W. E., Eurlings, L. W., et al.: A novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: a European coLlaboration on Acute decompeNsated Heart Failure: ELAN-HF Score. Heart, 2014, 100(2), 115–125.

  • 37

    Savarese, G., Musella, F., D’Amore, C., et al.: Changes of natriuretic peptides predict hospital admissions in patients with chronic heart failure. JACC Heart Fail., 2014, 2(2), 148–158.

  • 38

    Januzzi, J. L. Jr.: The role of natriuretic peptide testing in guiding chronic heart failure management: review of available data and recommendations for use. Arch. Cardiovasc. Dis., 2012, 105(1), 40–50.

  • 39

    Shah, M. R., Califf, R. M., Nohria, A., et al.: The STARBRITE Trial: a randomized, pilot study of B-type natriuretic peptide guided therapy in patients with advanced heart failure. J. Card. Fail., 2011, 17(8), 613–621.

  • 40

    Pfisterer, M., Buser, P., Rickli, H., et al.: BNP-guided vs. symptom-guided heart failure therapy: the Trial of Intensified vs. Standard Medical Therapy in Elderly Patients with Congestive Heart Failure (TIME-CHF) Randomized Trial. JAMA, 2009, 301(4), 383–392.

  • 41

    Lainchbury, J. G., Troughton, R. W., Strangman, K. M., et al.: N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J. Am. Coll. Cardiol., 2009, 55(1), 53–60.

  • 42

    Eurlings, L. W., von Pol, W. E., Kok, W. E., et al.: Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. J. Am. Coll. Cardiol., 2010, 56(25), 2090–2100.

  • 43

    Persson, H., Erntell, H., Eriksson, B., et al.: Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NT-proBNP Guided Management of Heart Failure – SIGNAL-HF (Swedish Intervention study – Guidelines and NT-proBNP AnaLysis in Heart Failure). Eur. J. Heart Fail., 2010, 12(12), 1300–1308.

  • 44

    Karlström, P., Alehagen, U., Boman, K., et al.: Corrigendum to ’Brain natriuretic peptide-guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: responders to treatment have a significantly better outcome’ [Eur J Heart Fail 2011; 13(10), 1096–1103]. Eur. J. Heart Fail., 2012, 14(5), 563.

  • 45

    Troughton, R. W., Frampton, C. M., Yandle, T. G., et al.: Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet, 2000, 355(9210), 1126–1130.

  • 46

    Jourdain, P., Jondeau, G., Funck, F., et al.: Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J. Am. Coll. Cardiol., 2007, 49(16), 1733–1739.

  • 47

    Berger, R., Moertl, D., Peter, S., et al.: N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure. A 3-arm, prospective, randomized pilot study. J. Am. Coll. Cardiol., 2010, 55(7), 645–653.

  • 48

    Januzzi, J. L. Jr., Rehman, S. U., Mohammed, A. A., et al.: Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J. Am. Coll. Cardiol., 2011, 58(18), 1881–1889.

  • 49

    Masson, S., Latini, R., Anand, I. S., et al.: Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin. Chem., 2006, 52(8), 1528–1538.

  • 50

    Felker, G. M., Hasselblad, V., Hernandez, A. F., et al.: Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am. Heart J., 2009, 158(3), 422–430.

  • 51

    Porapakkham, P., Porapakkham, P., Zimmet, H., et al.: B-type natriuretic peptide-guided heart failure therapy: a meta-analysis. Arch. Intern. Med., 2010, 170(6), 507–514.

  • 52

    Savarese, G., Trimarco, B., Dellegrottaglie, S., et al.: Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2686 patients in 12 randomized trials. PLoS ONE, 2013, 8, e58287.

  • 53

    Troughton, R. W., Frampton, C. M., Brunner-LaRocca, H. P., et al.: Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. Eur. Heart J., 2014, 35(23), 1559–1567.

  • 54

    McMurray, J. J., Packer, M., Desai, A. S., et al.: Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med., 2014, 371(11), 993–1004.

  • 55

    Boerrigter, G., Costello-Boerrigter, L. C., Harty, G. J., et al.: Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2007, 292(2), R897–R901.

  • 56

    Sanders-van Wijk, S., van Asselt, A. D., Rickli, H., et al.: Cost-effectiveness of N-terminal pro-B-type natriuretic-guided therapy in elderly heart failure patients: results from TIME-CHF (Trial of Intensified versus Standard Medical Therapy in Elderly Patients with Congestive Heart Failure). JACC Heart Fail., 2013, 1(1), 64–71.

  • 57

    Siebert, U., Januzzi, J. L. Jr., Beinfeld, M. T., et al.: Cost-effectiveness of using N-terminal pro-brain natriuretic peptide to guide the diagnostic assessment and management of dyspneic patients in the emergency department. Am. J. Cardiol., 2006, 98(6), 800–805.

  • 58

    Heidenreich, P. A., Gubens, M. A., Fonarow, G. C., et al.: Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. J. Am. Coll. Cardiol., 2004, 43(6), 1019–1026.

  • 59

    Horváth, L., Tomcsányi, J., Tóth, E.: Epidemiology and therapeutic practice of heart failure: national experience assessed with the use of financial databases. [A szívelégtelenség epidemiológiája és terápiás gyakorlata: hazai tapasztalatok a finanszírozási adatbázisok feldolgozásával.] IME, 2012, 11(5), 46–50. [Hungarian]

  • 60

    Tomcsányi, J., Nagy, E., Somlói, M., et al.: Left ventricular dysfunction and brain natriuretic peptide. [Bal kamra dysfunctio és az agyi natriuretikus peptid.] Cardiol. Hung., 2002, 32(4), 199–202. [Hungarian]

  • 61

    Szabó, G., Rigó, J. Jr., Nagy, B.: Physiology and clinical importance of the natriuretic peptide system. [Natriureticus peptidcsalád élettani jellemzői és klinikai szerepe.] Orv. Hetil., 2011, 152(26), 1025–1034. [Hungarian]